STK3 and ovarian cancer: Using 5-aza-20-deoxycytidine (DAC), a specific methyltransferase inhibitor, and Trichostatin A (TSA), a histone deacetylase inhibitor, we found that the mRNA expression level of STK3 in ovarian cancer cells was significantly increased after DAC treatment (P value <0.05), but not by TSA treatment.